Melco Crown Entertainment Limited (NASDAQ:MPEL) has obtained a mean price target of $16.25 by market experts. The research group First Call has reached this mean recommendation by taking into account the recommendations of leading analysts in the market. These market experts have disclosed projected earnings of $0.06 a share for the near-term quarter and $0.28 for this year.
The technical analysis of Melco Crown Entertainment Limit clearly shows that the moving average of 50-days of Melco Crown Entertainment Limited (NASDAQ:MPEL) stock is $13.44, and is trading $-0.27 points away or -2.01% from its 50-day moving average of $13.44. Further it is trading $-1.44 or -9.83% away its 200-day moving average of $14.61.
The 52-week high of Melco Crown Entertainment Limited (NASDAQ:MPEL) was $20.23 while $11.91 is the low in the same period. This state Melco Crown Entertainment Limit shares price has to travel more than $-7.06 to register a new high of 52-weeks or drop +10.58% to touch a new 52-week low point. MA here stands for moving average.
Taking the valuation aspect to reach the estimation of Melco Crown Entertainment Limit, investors use price-to-earnings ratio, which is truncated as P/E ratio. It assesses shares price by the relative expense of the stock. Melco Crown Entertainment Limited (NASDAQ:MPEL) ratio came in at 76.57, which was derived by dividing current price of stock by yearly earnings. Melco Crown Entertainment Limit stock recorded a close of $13.17 in last trading session, reaching a market cap of $6.69B.
Investors calculate the Price-to-Earnings-Growth ratio to get a clear view on the valuation of a firm. In the case of a higher PEG ratio, the shareholders look to sell their stock holdings. The undervalued stock has a PEG ratio of 0 or 1 while the fairly valued stock has the ratio of 1 and 2. The Melco Crown Entertainment Limited (NASDAQ:MPEL) PEG ratio is at 5.92.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...